By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Hogehilweg 7
1101 CA
Amsterdam Zuid-Oost      The Netherlands
Phone: 31-20-567-0900 Fax: 31-20-567-0999



Company News
PlasmaTech Biopharmaceuticals Signs Expanded MuGard Licensing Agreement With Norgine For Australia And New Zealand Territories 10/27/2014 8:24:29 AM
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014 7:39:25 AM
Norgine Enrolls First Patient In The Phase 3 NOCT Study To Evaluate Bowel Cleansing Efficacy Of NER1006, A Novel, Low Volume Bowel Preparation, Vs. Trisulfate 10/3/2014 7:25:39 AM
Access Pharmaceuticals (ACCP) Announces European License Agreement With Norgine 8/7/2014 7:50:59 AM
Norgine Release: New Data Show How Hepatic Encephalopathy Contributes To Burden Of Liver Disease 4/11/2014 9:59:24 AM
Altacor Strengthens Commercial Capability With Norgine Collaboration - for the Promotion of Altacor's Dry Eye Product Clinitas® in the UK 7/1/2013 11:01:56 AM
Norgine Release: PBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia 5/28/2013 9:07:39 AM
Tranzyme Pharma (TZYM)/Norgine GI Drug Fails Second Late-stage Trial 5/28/2012 11:17:24 PM
Tranzyme Pharma (TZYM) and Norgine Bowel Drug Fails Trial 3/12/2012 6:58:33 AM
Tranzyme Pharma and Norgine Complete Enrollment in ULISES 008, the Second of Two Phase 3 Pivotal Trials of Ulimorelin 2/28/2012 9:35:14 AM